Lightlake Therapeutics Inc. (LLTP) to Present at 4th Annual OneMedForumNY 2013
6/18/2013 9:15:01 AM
More...
|
Lightlake Therapeutics Inc. (LLTP)’ Binge Eating Disorder Treatment Phase II Trial Results Presented at American Psychiatric Association 2013 Annual Meeting
5/23/2013 11:11:29 AM
More...
|
Lightlake Therapeutics Inc. (LLTP)’ Binge Eating Disorder Treatment Phase II Trial Results Presented at American Psychiatric Association 2013 Annual Meeting
5/23/2013 8:07:09 AM
More...
|
Lightlake Therapeutics Inc. (LLTP) to Develop Opioid Drug Treatment in Collaboration With the National Institute on Drug Abuse (NIDA)
4/24/2013 11:32:09 AM
More...
|
Lightlake Therapeutics Inc. (LLTP) Announces Phase II Clinical Trial Results of Treatment for Binge Eating Disorder Accepted at the American Psychiatric Association Annual Meeting
3/27/2013 11:15:20 AM
More...
|
Lightlake Therapeutics Inc. (LLTP) Appoints Board Member as New Chief Financial Officer
11/30/2012 8:29:28 AM
More...
|
Lightlake Therapeutics Inc. (LLTP) Appoints Dr. David Kessler as Strategic Advisor
9/24/2012 10:37:00 AM
More...
|
Lightlake Therapeutics Inc. (LLTP) Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
8/8/2012 10:48:47 AM
More...
|
Lightlake Therapeutics Inc. (LLTP) Announces Positive Preliminary Phase II Clinical Trial Results of Binge Eating Disorder Treatment
5/3/2012 7:19:35 AM
More...
|
Lightlake Therapeutics Inc. Appoints New Board Member
4/17/2012 10:39:03 AM
More...
|
|